Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations


2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest
 March 28, 2022 -
March 30, 2022
 8:00am - 5:00pm EDT

Cardiff Oncology CEO, Mark Erlander, PhD, will participate in a Fireside Chat on Monday, March 28th at 2:30 pm EDT.  Additionally, a pre-recorded overview of Cardiff Oncology’s clinical and corporate strategy will be available throughout the duration of the conference - March 28th - 30th, and streamed live on M-Vest. To attend, sign up to become an M-Vest member here.